Pyxis Oncology
PYXS
51 hedge funds and large institutions have $200M invested in Pyxis Oncology in 2021 Q4 according to their latest regulatory filings, with 51 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
55.98% more ownership
Funds ownership: 0% → 55.98% (+56%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$26.1M |
| 2 |
RI
RTW Investments
New York
|
+$24.3M |
| 3 |
PA
Perceptive Advisors
New York
|
+$22.3M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
+$20.5M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$17.4M |
Top Sellers
PYXS Hedge Fund Activity: Q4 2021 in Review
51 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Pyxis Oncology (PYXS) for Q4 2021, worth a combined $200M.
Buyers outnumbered sellers: 51 funds opened new PYXS positions and 0 closed out — a net gain of 51 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $26.1M.
- 51 institutional investors held Pyxis Oncology (PYXS) as of Q4 2021, up from 0 in Q3 2021.
- Funds reported $200M of Pyxis Oncology stock for Q4 2021.
- 51 funds opened new Pyxis Oncology positions in Q4 2021 and 0 closed out, a net change of +51 holders.
- The largest Pyxis Oncology buyer in Q4 2021 was RA Capital Management, an estimated $26.1M added.
Based on aggregated 13F filings for Q4 2021.